OXIGENE, INC.

Company

Oncotelic Therapeutics, Inc.

Filed

May 28, 2010

Period of Report

June 30, 2010

Accession Number

0000950123-10-054311

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →